Search

Travere Therapeutics Inc

Abierto

51.82 -0.59

Resumen

Variación precio

24h

Actual

Mínimo

51.47

Máximo

53.22

Métricas clave

By Trading Economics

Ingresos

1.8M

-35M

Ventas

42M

170M

BPA

-0.37

Margen de beneficios

-20.519

Empleados

497

EBITDA

-24M

-33M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+45.64% upside

Dividendos

By Acuity

Próximas Ganancias

29 oct 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

250M

5.4B

Apertura anterior

52.41

Cierre anterior

51.82

Travere Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

11 oct 2026, 23:51 UTC

China's Inflation Rate YoY for September 2026 set to release on October 14, with expectations of a slight increase to 0.1%, amid cautious market sentiment influenced by global economic factors and U.S. Treasury yields.

11 oct 2026, 23:51 UTC

China's PPI data release on October 14, 2026, expected to show a year-on-year increase of 4.5%, amid cautious optimism and potential implications for global inflation and monetary policy.

11 oct 2026, 23:51 UTC

China's inflation rate expected to rise by 0.3% MoM amid cautious market sentiment and global economic pressures ahead of key CPI reports.

11 oct 2026, 23:41 UTC

U.S. Import Prices Report on October 16 Forecasts 0.7% Increase Amid Cautious Market Sentiment and Geopolitical Tensions

11 oct 2026, 23:41 UTC

U.S. Export Prices Expected to Rise 0.01% in September Amid Mixed Economic Sentiment and Cautious Market Optimism

11 oct 2026, 23:31 UTC

Canada's Housing Starts Data Release on October 16 Forecasts Decline to 237.5K Units Amid Cautious Market Sentiment

11 oct 2026, 23:21 UTC

Core Producer Price Index (PPI) for September 2026 set to release on October 15, with a forecasted increase of 0.3%, amid mixed economic sentiment and rising Treasury yields impacting investor optimism.

11 oct 2026, 23:21 UTC

Market Braces for September PPI Release Amid Rising Treasury Yields and Fed Rate Hike Speculation

11 oct 2026, 23:21 UTC

Market Awaits Philadelphia Fed Manufacturing Index Release Amid Mixed Economic Sentiment and Caution Over Inflationary Pressures.

11 oct 2026, 23:21 UTC

Investors Brace for NY Empire State Manufacturing Index Release Amid High Treasury Yields and Inflation Concerns on October 15, 2026.

11 oct 2026, 23:11 UTC

Australia's Full-Time Employment Change Data Set for Release on October 15, Anticipated to Reflect Economic Resilience Amid Global Challenges.

11 oct 2026, 23:11 UTC

Australia's September 2026 unemployment rate forecasted to rise to 4.6%, raising market concerns ahead of the October release amid global economic volatility.

11 oct 2026, 23:11 UTC

Australia's Employment Change Report on October 15 Expected to Show Job Growth Amid Positive Labor Market Sentiment, but Analysts Warn of Potential Volatility.

11 oct 2026, 23:01 UTC

Investors Brace for Volatility Ahead of October 14 CPI Release Amid Rising Inflation Concerns and Fed Rate Hike Speculations.

11 oct 2026, 23:01 UTC

Core Inflation Rate for September 2026 set to rise by 0.2%, influencing market sentiment and Federal Reserve rate hike expectations ahead of key CPI reports.

11 oct 2026, 23:01 UTC

U.S. CPI Expected to Rise to 336.67 Amid Inflation Concerns and Market Volatility Ahead of October Release

11 oct 2026, 23:01 UTC

Core Inflation Rate YoY for September 2026 set to rise slightly to 2.5%, as markets brace for potential Federal Reserve interest rate hikes amid geopolitical tensions and high Treasury yields.

11 oct 2026, 23:01 UTC

Investors Brace for U.S. CPI Release on October 14, Anticipating Inflation Rise to 3.7% and Potential Fed Policy Shifts

11 oct 2026, 23:01 UTC

U.S. Inflation Rate Expected to Rise 0.6% in September Amidst Market Caution and High Treasury Yields Ahead of Federal Reserve Decisions

11 oct 2026, 23:01 UTC

Macro News

Gold prices are declining amid escalating geopolitical tensions and rising U.S. Treasury yields, remaining below its 20-day moving average.

11 oct 2026, 23:01 UTC

The EUR/NOK is advancing in early trading, influenced by geopolitical tensions and rising yields.

11 oct 2026, 23:01 UTC

The EUR/SEK is trading higher in early trading, rebounding after a slight dip amid rising yields and geopolitical tensions affecting market sentiment.

11 oct 2026, 22:51 UTC

Brazil's Retail Sales MoM data for August 2026, expected to rise by 0.8%, set for release on October 15 amid cautious economic sentiment influenced by global trends.

11 oct 2026, 22:31 UTC

Japan's Machinery Orders MoM data set for October 14, with a modest growth forecast of 0.03% amid cautious market sentiment following recent volatility.

11 oct 2026, 22:31 UTC

RBA Meeting Minutes on October 13 Expected to Address Inflation Concerns and Future Monetary Policy Adjustments.

11 oct 2026, 22:31 UTC

Australia's NAB Business Confidence Report Set for Release Amidst Cautious Market Sentiment and Ongoing Economic Challenges

11 oct 2026, 22:21 UTC

Singapore's Q3 2026 GDP Growth Rate Expected at 0.9%, Amid Cautious Optimism and Input Cost Concerns

11 oct 2026, 22:21 UTC

Mortgage Rates Hit 7.49% Amid Rising Treasury Yields and Inflation Concerns, Sparking Caution in Housing Market Ahead of Upcoming Data Release

11 oct 2026, 22:11 UTC

Brazil's Central Bank to Provide Key Interest Rate Insights Amid Political Turmoil on October 13, 2026.

11 oct 2026, 22:01 UTC

South Korea's September 2026 unemployment rate release on October 15 expected to reveal job market stability amid global inflation concerns.

Comparación entre iguales

Cambio de precio

Travere Therapeutics Inc previsión

Precio Objetivo

By TipRanks

45.64% repunte

Estimación a 12 Meses

Media 75.917 USD  45.64%

Máximo 90 USD

Mínimo 62 USD

De acuerdo con 12 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Travere Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

12 ratings

11

Comprar

1

Mantener

0

Vender

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Travere Therapeutics Inc

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.